Form 13D/A PRECIGEN For: 31 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Precigen Inc (PGEN)
Precigen Inc stock price live, this page displays NASDAQ PGEN stock exchange data. View the PGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precigen Inc real time stock price chart below.
What Is the Precigen Inc Stock Price Today?
The Precigen Inc stock price today is 3.870.
What Is the Stock Symbol for Precigen Inc?
The stock symbol for Precigen Inc is ""PGEN.""
What Stock Exchange Does Precigen Inc Trade On?
Precigen Inc is listed and trades on the NASDAQ stock exchange.
Is Precigen Inc a Good Stock to Buy?
Determining whether Precigen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PGEN quote. (ISIN: US74017N1054) - Test -{{UPSIDE_OR_DOWNSIDE}} - {{DIVIDEND_YIELD}} - {{CURRENT_YEAR}}
What Is the Precigen Inc Stock Price Today?
The Precigen Inc stock price today is 3.870.
What Is the Stock Symbol for Precigen Inc?
The stock symbol for Precigen Inc is ""PGEN.""
What Stock Exchange Does Precigen Inc Trade On?
Precigen Inc is listed and trades on the NASDAQ stock exchange.
Is Precigen Inc a Good Stock to Buy?
Determining whether Precigen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PGEN quote. (ISIN: US74017N1054) - Test -{{UPSIDE_OR_DOWNSIDE}} - {{DIVIDEND_YIELD}} - {{CURRENT_YEAR}}
Fair Value
An estimate of a Precigen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.290
3.980
52 wk Range
1.110
5.465
Unusual trading volume
1/2
Fair Value
An estimate of a Precigen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2903.980
52 wk Range
1.1105.465
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Precigen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
9.500
Upside
+145.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen Inc SWOT Analysis
Gene Therapy Pionee | Precigen's PRGN-2012 for RRP treatment nears FDA decision, potentially revolutionizing care for an expanded patient population of 27,000 in the U.S. |
Commercial Readiness | Explore Precigen's strategic preparations for PRGN-2012's launch, including manufacturing upgrades and targeted marketing to 500 key prescribers. |
Pipeline Potential | Delve into Precigen's diverse portfolio, featuring promising candidates like PRGN-2009 for cervical cancer and PRGN-3006 for AML, poised for pivotal trials. |
Financial Outlook | Analyst price targets range from $5 to $7, reflecting optimism about Precigen's extended cash runway and potential for breakthrough gene therapies. |
Precigen Inc Earnings Call Summary for Q4/2025
- Precigen reported 2025 revenue of $9.7M, up 149% YoY, beating forecast of $8.29M driven by Papzimeos launch in November.
- Company posted net loss of $429.6M ($1.37/share); adjusted loss of $111.1M ($0.35/share) matched EPS expectations.
- Q1 2026 revenue projected to exceed $18M, representing 429% sequential growth; targeting cash flow breakeven by end of 2026.
- Over 300 patients enrolled in Papzimeos support hub; executives highlight product's potential as new standard of care for adult RRP.
- Stock declined 0.96% to $3.1 in aftermarket trading; analyst price targets range $8-$9 despite profitability concerns.
Last Updated: 25/03/2026, 22:22
Read Full TranscriptCompare PGEN to Peers and Sector
Metrics to compare | PGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −2.0x | −0.4x | |
PEG Ratio | 0.01 | 0.17 | 0.00 | |
Price/Book | 65.5x | 3.7x | 2.6x | |
Price / LTM Sales | 141.4x | 5.2x | 3.1x | |
Upside (Analyst Target) | 192.3% | 427.4% | 56.1% | |
Fair Value Upside | Unlock | 6.7% | 8.1% | Unlock |
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 9.500
(+145.48% Upside)
Earnings
Latest Release
Mar 25, 2026
EPS / Forecast
-0.07 / -0.08
Revenue / Forecast
4.58M / 8.29M
People Also Watch
FAQ
What Is the Precigen (PGEN) Stock Price Today?
The Precigen stock price today is 3.870 USD.
What Stock Exchange Does Precigen Trade On?
Precigen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Precigen?
The stock symbol for Precigen is "PGEN."
What Is the Precigen (PGEN) Afterhours Price Today? (Afterhours variable test: 3.790) Current Date: Apr 01, 2026
After hours price: 3.790. After hours price change (units): -0.080. Price change percentage: -2.070%
What Is the Precigen Market Cap?
As of today, Precigen market cap is 1.350B USD.
What Is Precigen's Earnings Per Share (TTM)?
The Precigen EPS (TTM) is -1.373.
When Is the Next Precigen Earnings Date?
Precigen will release its next earnings report on May 11, 2026.
From a Technical Analysis Perspective, Is PGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Precigen Stock Split?
Precigen has split 0 times.
How Many Employees Does Precigen Have?
Precigen has 160 employees.
What is the current trading status of Precigen (PGEN)?
As of Apr 01, 2026, Precigen (PGEN) is trading at a price of 3.870 USD, with a previous close of 3.250 USD. The stock has fluctuated within a day range of 3.290 USD to 3.980 USD, while its 52-week range spans from 1.110 USD to 5.465 USD.
What Is Precigen (PGEN) Price Target According to Analysts?
The average 12-month price target for Precigen is 9.500 USD, with a high estimate of 10 USD and a low estimate of 9 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +145.48% Upside potential.
What Is the PGEN Premarket Price?
PGEN's last pre-market stock price is 3.290 USD. The pre-market share volume is 6,840.000, and the stock has decreased by 0.040, or 1.230%.
What Is the PGEN After Hours Price?
PGEN's last after hours stock price is 3.790 USD, the stock has decreased by -0.080, or -2.070%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.